OSE Immunotherapeutics SA (EPA:OSE)

France flag France · Delayed Price · Currency is EUR
6.72
-0.09 (-1.32%)
Oct 7, 2025, 5:38 PM CET
-1.32%
Market Cap152.57M
Revenue (ttm)83.44M
Net Income (ttm)37.45M
Shares Out22.42M
EPS (ttm)1.46
PE Ratio4.66
Forward PE7.52
Dividendn/a
Ex-Dividend Daten/a
Volume92,968
Average Volume155,867
Open6.84
Previous Close6.81
Day's Range6.65 - 6.89
52-Week Range4.42 - 11.58
Beta0.45
RSI59.06
Earnings DateSep 26, 2025

About OSE Immunotherapeutics

OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. Its products include Tedopi that is in Phase III clinical trial for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; OSE-279, which is in a Phase I/II clinical trial in patients with advanced solid tumors or lymphomas; OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 64
Stock Exchange Euronext Paris
Ticker Symbol OSE
Full Company Profile

Financial Performance

Financial Statements

News

OSE Immunotherapeutics (ORPOF) Appoints Interim CEO Marc Le Bozec

OSE Immunotherapeutics (ORPOF) Appoints Interim CEO Marc Le Bozec

4 days ago - GuruFocus

OSE Immunotherapeutics SA (ORPOF) Shareholder/Analyst Call Transcript

OSE Immunotherapeutics SA (OTC:ORPOF) Shareholder/Analyst Call September 18, 2025 12:00 PM EDTCompany ParticipantsFiona Olivier - Chief Corporate Affairs...

19 days ago - Seeking Alpha